Galapagos NV (NASDAQ: GLPG) announced today that the Company will be moving filgotinib, its highly selective JAK1 inhibitor, into Phase ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News Hot Corp. News Management Comments

Credit Suisse Downgrades Galapagos NV (GLPG) to NeutralSeptember 28, 2015 6:48 AM Cowen Remains Bullish on Galapagos NV (GLPG) After AbbVie (ABBV) Declined to Opt-In for Phase III Development of Filgotinib September 25, 2015 3:14 PM Galapagos to advance filgotinib to Phase 3 in rheumatoid arthritisSeptember 25, 2015 10:49 AM UPDATE: AbbVie (ABBV) to Advance ABT-494, Will Not Exercise Rights to Galapagos' (GLPG) FilgotinibSeptember 25, 2015 7:14 AM